We are investigating the effects of Durvalumab in patients with early-stage triple-negative breast cancer before surgery. This study aims to see if it can improve treatment outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Triple Negative Breast Cancer (TNBC) is a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER2 gene. This makes it more challenging to treat, as it does not respond to hormonal therapy or therapies that target HER2.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.